Hupolipidemic activity of (--)-hydroxycitrate.
The influence of (--)-hydroxycitrate, a potent competitive inhibitor of adenosine triphosphate (ATP) citrate lyase, on serum triglyceride and cholesterol levels, and in vitro and in vivo rates of hepatic fatty acid and chloesterol synthesis was investigated in normal and hyperlipidemic rat model systems. (--)-Hydroxycitrate reduced equivalently the biosynthesis of triglycerides, phospholipids, cholesterol, diglycerides, cholesteryl esters, and free fatty acids in isolated liver cells. In vivo hepatic rates of fatty acid and cholesterol synthesis determined in meal-fed normolipidemic rats were suppressed significantly by the oral administration of (--)-hydroxycitrate for 6 hr, when control animals exhibited maximal rates of lipid synthesis; serum triglyceride and cholesterol levels were significantly reduced by (--)-hydroxycitrate. In two hypertriglyceridemic models-the genetically obese Zucker rat and the fructose-treated rat-elevated triglyceride levels were due, in part, to enhance hepatic rates of fatty acid synthesis. (--)-Hydroxycitrate significantly reduced the hypertriglyceridemia and hyperlipogensisi in both models. the marked hypertriglyceridemia exhibited by the triton-treated rat was only minimally due to increased hepatic lipogenesis;(--)-hydroxycitrate significantly inhibited both serum triglyceride levels and lipogenesis in this model.
D000818:Animals; D002784:Cholesterol / Q000096:biosynthesis / Q000097:blood; D002951:Citrates / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism; D050356:Lipid Metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D014280:Triglycerides / Q000097:blood
D002951:Citrates; D014280:Triglycerides; C007999:hydroxycitric acid; D002784:Cholesterol